Literature DB >> 9643527

Treatment of chronic myelogenous leukaemia.

B Simonsson1.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9643527     DOI： 10.1007/bf02787341

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  34 in total

1.  Indications for marrow transplantation in chronic myelogenous leukemia.

Authors:  E D Thomas; R A Clift
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

2.  Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

Authors:  J T Slattery; R A Clift; C D Buckner; J Radich; B Storer; W I Bensinger; E Soll; C Anasetti; R Bowden; E Bryant; T Chauncey; H J Deeg; K C Doney; M Flowers; T Gooley; J A Hansen; P J Martin; G B McDonald; R Nash; E W Petersdorf; J E Sanders; G Schoch; P Stewart; R Storb; K M Sullivan; E D Thomas; R P Witherspoon; F R Appelbaum
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

3.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

4.  Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).

Authors:  I Cunningham; T Gee; M Dowling; R Chaganti; R Bailey; S Hopfan; L Bowden; A Turnbull; W Knapper; B Clarkson
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

5.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

6.  Bone marrow transplantation for chronic myelogenous leukemia.

Authors:  M R Litzow; A Tefferi
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

Review 7.  Treatment of myelogenous leukemia: current status and investigational options.

Authors:  H M Kantarjian; S O'Brien; P Anderlini; M Talpaz
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

8.  Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

Authors:  R Hehlmann; H Heimpel; J Hasford; H J Kolb; H Pralle; D K Hossfeld; W Queisser; H Löffler; B Heinze; A Georgii
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

9.  Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups.

Authors:  P B McGlave; P De Fabritiis; A Deisseroth; J Goldman; M Barnett; J Reiffers; B Simonsson; A Carella; D Aeppli
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

10.  Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia.

Authors:  B Simonsson; G Oberg; A Killander; M Björeman; M Börkholm; G Gahrton; R Hast; I Turesson; A M Udén; C Malm
Journal:  Stem Cells       Date:  1993-10       Impact factor: 6.277
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.